Recently, a broader mutation testing of RAS gene (at exons 2, 3, or 4 of both KRAS and NRAS) has been validated for treatment personalization in advanced colorectal cancer through the support of several studies [21]. This evidence concerns the gene NRAS and colorectal cancer.